Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Selinexor in Advanced Gynaecologic Malignancies
2013-003650-24Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in gynecological cancer and Cervical Cancer (CC), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Disease control rate. Started Jan 2014; status: completed.
02
Drugs
selinexor
03
Conditions
gynecological cancerCervical Cancer (CC)
Beyond the preview
Go deeper on 2013-003650-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003650-24.